Claims for Patent: 3,995,021

Summary for Patent: 3,995,021

Title:	Antigens of 5,5\'alkylphenyl barbituric acids and related hydantoin compounds
Abstract:	Antigens comprising 5,5\'-alkylphenyl barbituric acid haptens and related 5,5\'-phenylhydantoin haptens coupled to a carrier through an azo group connected meta or para on the phenyl ring are prepared by diazotization of the corresponding amine. Specific antibodies are raised in animals and used in radioimmuno assays for the corresponding hapten.
Inventor(s):	Gross; Stanley Joseph (Encino, CA)
Assignee:	Biological Developments, Inc. (Encino, CA)
Application Number:	05/543,012
Patent Claims:	1. A synthetic antigen comprising a phenyl substituted hapten selected from the class consisting of phenobarbital, phenyl methyl barbituric acid, mephobarbital and hydantoin haptens of the following formula: ##SPC3## in which X is selected from the class consisting of hydrogen, methyl and ethyl and Y is selected from the class consisting of hydrogen, ethyl and phenyl; coupled through an azo group on the phenyl ring of said hapten to a macromolecule carrier which confers antigenicity, said azo group being selected from the class consisting of a meta azo radical and a para azo radical. 2. The antigen of claim 1 comprising a plurality of the hapten moieties connected to a single carrier moiety. 3. The antigen of claim 2 wherein the carrier is selected from the class consisting of keyhole limpet hemocyanin, bovine serum albumin, human immunogammaglobulin and thyroglobulin and the azo group is connected from the hapten moiety directly to a pendant group of the carrier, said pentant group being selected from the class consisting of a tyrosyl radical and a histidyl radical. 4. Protein meta azo phenobarbital where the protein has a pendant group selected from the class consisting of a tyrosyl radical and a histidyl radical and is connected to the azo group at a diazotizable ring carbon of said pendant group. 5. A method of preparing an antigen according to claim 1 comprising diazotization of a meta or para amino phenyl substituted hapten selected from the class consisting of meta and para aminophenobarbital, meta and para aminophenyl methyl barbituric acid, meta and para aminomephobarbital and meta and para amino phenyl hydantoins of the following formula: ##SPC4## in which X is selected from the class consisting of hydrogen, methyl and ethyl, Y is selected from the class consisting of hydrogen, ethyl, phenyl, meta aminophenyl, and para aminophenyl, R.sub.1 is selected from the class consisting of hydrogen and amino and R.sub.2 is selected from the class consisting of hydrogen and amino, and R.sub.1 and R.sub.2 are different; and coupling the resulting diazonium salt to a diazotizable carbon of an aromatic ring having such a carbon, the aromatic ring being coupled to a macromolecule carrier which confers antigenicity. 6. A method according to claim 5 wherein the carrier is a natural protein having a pendant group selected from the class consisting of a tyrosyl radical and a histidyl radical group and the coupling is effected directly to said group. 7. Antibody raised by the antigen of claim 1 and binding with said phenyl substituted hapten. 8. Antibody raised by the antigen of claim 4 and binding with said protein meta azo phenobarbital. 9. An immunochemical method of assaying for the presence of a phenyl substituted target hapten in a sample, said target hapten being selected from the class consisting of phenobarbital, phenylmethyl barbituric acid, mephobartibal and hydantoin haptens of the following formula: ##SPC5## in which X is selected from the class consisting of hydrogen, methyl and ethyl and Y is selected from the class consisting of hydrogen, ethyl and phenyl; wherein said method employs an antibody obtained by the immunologic response of a vertebrate animal to administration of an antigen according to claim 1 and wherein said antibody is specific to the target, said method also employing a standard, the antibody binding with the target to form an antibody-target complex and competitively binding with the standard to form an antibody-standard complex, the antibody-standard complex having an artificially introduced radiation label enabling the complex to be assayed quantitatively by measurement of radiation emanating from it, the affinities of the antibody for the standard and for the target being known quantitatively, said method comprising allowing a known quantity of the sample and a known quantity of the standard to compete for binding with a known quantity of the antibody and determining the radiation emanating from the antibody-standard complex, thereby enabling the quantity of antibody-bound standard to be calculated and the quantity of target in the sample to be deduced. 10. The method of claim 9 wherein the label is radioactive and the antibody-standard complex is separated from any non-complexed labeled material after allowing competition binding and before determination of the emanated radiation. 11. The method of claim 9 wherein the label is fluorescent and the standard is provided with a chemical moiety giving it a fluorescence spectrum overlapping the natural fluorescence spectrum of the antibody, whereby the complex can be assayed by measurement of the perturbation of the antibody fluorescence due to its binding with the standard. 12. The antibody of claim 7 insolubilized by securing it to a solid matrix.

Details for Patent 3,995,021

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		1993-11-30
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		1993-11-30
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		1993-11-30
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		1993-11-30
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		1993-11-30
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		1993-11-30